Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5274850 | 1.00 | CTSK (0.52) | CTSKMEN1FAAHMAPK1KMT2A | |
| SCHEMBL5272733 | 1.00 | CTSK (0.52) | CTSKMEN1FAAHMAPK1KMT2A | |
| SCHEMBL5269470 | 1.00 | CTSK (0.52) | CTSKMEN1FAAHMAPK1KMT2A | |
| SCHEMBL8777248 | 0.94 | CTSK (0.55) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL11122028 | 0.88 | CA1 (0.44) | CTSKMEN1KMT2ACA1CA2 | |
| SCHEMBL14923714 | 0.87 | CA1 (0.49) | CTSKKMT2ACA1CA2CA7 | |
| SCHEMBL30989585 | 0.84 | CTSK (0.49) | CTSKMEN1FAAHMAPK1KMT2A | |
| SCHEMBL30989580 | 0.84 | CTSK (0.49) | CTSKMEN1FAAHMAPK1KMT2A | |
| SCHEMBL30989578 | 0.84 | CTSK (0.49) | CTSKMEN1FAAHMAPK1KMT2A | |
| SCHEMBL5274937 | 0.83 | CTSK (0.55) | CTSKMEN1FAAHMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1287006-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2007-10-24 | — | — | EP | disclosed |
| US-7138547-B2 | Antitumoral compounds | PHARMA MAR, S.A. | 2006-11-21 | — | — | US | disclosed |
| US-20040048834-A1 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048834-A1 | Antitumoral compounds | HCCS, MSR1, SUCNR1 | CTSK 4264/4885MEN1 3148/4885FAAH 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.